Following a stroke, regaining the ability to walk is a key part of rehabilitation. For some patients, traditional walking aids may not be enough due to balance issues, muscle weakness, or fatigue. In response, the French company Lifebloom has developed a device called Oxilio, which combines the features of a wheelchair and an exoskeleton. This innovation is intended for patients who need more support than a standard walking aid can provide but are not yet ready to walk independently. Oxilio allows users to stand and move with reduced weight load—up to 80% less—thereby decreasing the risk of falling and helping them practice walking in a safer way. Unlike traditional rehabilitation methods, Oxilio doesn’t force movement but instead supports the user's own efforts, allowing them to initiate movement with their remaining muscle strength. The device includes a fall prevention system with side panels that support the pelvis. If the user loses balance or bends their legs, Oxilio automatically seats them, offering an added layer of safety. It is also equipped with sensors that monitor pressure, movement, and orientation in real time. These sensors are part of a larger connected ecosystem that collects and analyzes data on the user’s posture and activity. This information is sent to a digital care platform, enabling physiotherapists to remotely monitor progress and adjust rehabilitation plans as needed. Lifebloom has already begun mass production of Oxilio, and its deployment is underway in dozens of healthcare facilities. The device is also being considered for home use, offering greater flexibility for patients. Before its full market launch, the Oxilio exoskeleton was tested at the Pitié-Salpêtrière Hospital in Paris, where it showed promising results. Patients using Oxilio were able to stand for significantly longer periods—up to six times more than with traditional methods—helping prevent muscle atrophy and improving systemic functions like digestion and blood circulation. While initially designed for stroke survivors, Oxilio’s potential extends beyond this group. The device is also being explored for patients with neurodegenerative conditions such as multiple sclerosis or Parkinson’s disease, as well as for older adults experiencing age-related mobility challenges. By offering a safer, more effective way to practice movement, Oxilio aims to enhance the quality of life and independence of individuals with various mobility impairments.